These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35947811)

  • 1. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update Q and A.
    Crews JR; Kirshner JJ; Temin S
    JCO Oncol Pract; 2022 Nov; 18(11):753-755. PubMed ID: 35947811
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update Q and A.
    Ramakrishna N; Anders CK; Temin S
    JCO Oncol Pract; 2022 Nov; 18(11):756-758. PubMed ID: 35947812
    [No Abstract]   [Full Text] [Related]  

  • 3. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.
    Giordano SH; Temin S; Chandarlapaty S; Crews JR; Esteva FJ; Kirshner JJ; Krop IE; Levinson J; Lin NU; Modi S; Patt DA; Perlmutter J; Ramakrishna N; Winer EP; Davidson NE
    J Clin Oncol; 2018 Sep; 36(26):2736-2740. PubMed ID: 29939838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer and Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A.
    Moy B; Wolff AC; Rumble RB; Allison KH; Carey LA
    JCO Oncol Pract; 2023 Aug; 19(8):547-550. PubMed ID: 37284796
    [No Abstract]   [Full Text] [Related]  

  • 5. Testing for
    Burstein HJ; DeMichele A; Somerfield MR; Henry NL;
    J Clin Oncol; 2023 Jun; 41(18):3423-3425. PubMed ID: 37196213
    [No Abstract]   [Full Text] [Related]  

  • 6. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
    Burstein HJ; Somerfield MR; Barton DL; Dorris A; Fallowfield LJ; Jain D; Johnston SRD; Korde LA; Litton JK; Macrae ER; Peterson LL; Vikas P; Yung RL; Rugo HS
    J Clin Oncol; 2021 Dec; 39(35):3959-3977. PubMed ID: 34324367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update Summary.
    Giordano SH; Temin S; Davidson NE
    J Oncol Pract; 2018 Aug; 14(8):501-504. PubMed ID: 29989839
    [No Abstract]   [Full Text] [Related]  

  • 8. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.
    Ramakrishna N; Temin S; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Giordano SH; Kirshner JJ; Krop IE; Levinson J; Modi S; Patt DA; Perlmutter J; Winer EP; Lin NU
    J Clin Oncol; 2018 Sep; 36(27):2804-2807. PubMed ID: 29939840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update.
    Giordano SH; Franzoi MAB; Temin S; Anders CK; Chandarlapaty S; Crews JR; Kirshner JJ; Krop IE; Lin NU; Morikawa A; Patt DA; Perlmutter J; Ramakrishna N; Davidson NE
    J Clin Oncol; 2022 Aug; 40(23):2612-2635. PubMed ID: 35640077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update.
    Moy B; Rumble RB; Carey LA;
    J Clin Oncol; 2022 Sep; 40(26):3088-3090. PubMed ID: 35926153
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update.
    Ramakrishna N; Anders CK; Lin NU; Morikawa A; Temin S; Chandarlapaty S; Crews JR; Davidson NE; Franzoi MAB; Kirshner JJ; Krop IE; Patt DA; Perlmutter J; Giordano SH
    J Clin Oncol; 2022 Aug; 40(23):2636-2655. PubMed ID: 35640075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update Summary.
    Ramakrishna N; Temin S; Lin NU
    J Oncol Pract; 2018 Aug; 14(8):505-507. PubMed ID: 29989840
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of the 2013 ASCO-CAP HER2 Testing Guideline on the Management of IHC/HER2 2+ Invasive Breast Cancer.
    Yamada M; Kubo M; Yamamoto H; Yamashita N; Kai M; Zaguirre K; Kaneshiro K; Shimazaki A; Hayashi S; Kawaji H; Mori M; Oda Y; Nakamura M
    Anticancer Res; 2021 Aug; 41(8):4143-4149. PubMed ID: 34281885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
    Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
    Moy B; Rumble RB; Come SE; Davidson NE; Di Leo A; Gralow JR; Hortobagyi GN; Yee D; Smith IE; Chavez-MacGregor M; Nanda R; McArthur HL; Spring L; Reeder-Hayes KE; Ruddy KJ; Unger PS; Vinayak S; Irvin WJ; Armaghani A; Danso MA; Dickson N; Turner SS; Perkins CL; Carey LA
    J Clin Oncol; 2021 Dec; 39(35):3938-3958. PubMed ID: 34324366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
    Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
    Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the 2018 ASCO/CAP HER2 Guideline Focused Update.
    Gordian-Arroyo AM; Zynger DL; Tozbikian GH
    Am J Clin Pathol; 2019 Jun; 152(1):17-26. PubMed ID: 30958889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ASCO-CAP guidelines for breast predictive factor testing: an update.
    Hammond ME
    Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):499-500. PubMed ID: 22089488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
    van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
    Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.
    Denduluri N; Somerfield MR; Eisen A; Holloway JN; Hurria A; King TA; Lyman GH; Partridge AH; Telli ML; Trudeau ME; Wolff AC
    J Clin Oncol; 2016 Jul; 34(20):2416-27. PubMed ID: 27091714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.